Imaging plays a crucial role in the diagnosis and management of lung cancer, which remains a leading cause of cancer-related deaths worldwide. Radiological methods like CT (including low-dose) and PET, have become essential for early detection, staging, and ongoing monitoring… Read More
Glioblastoma multiforme (GBM) is the most malignant and prevalent subtype of glioma, representing the most common primary brain tumor in adults. MRI is considered the gold standard for assessing glioblastoma. However, structural MRI alone is insufficient for accurately interpreting treatment-related… Read More
Gastrointestinal Stromal Tumors (GIST) pose unique challenges in clinical settings due to their distinct molecular features and behaviors. Imaging plays a pivotal role in evaluating diagnosis and treatment agents in GIST clinical trials. Various imaging techniques are utilized for monitoring… Read More
Sarcomas and bone tumors pose a distinctive challenge in oncology imaging, necessitating standardized protocols for precise tumor response determination in clinical trials. Multiple imaging techniques are needed to address the heterogeneity of these tumors. Imaging Endpoints applies the leading and… Read More
Hematologic cancers, originating from lymphoid and myeloid cell lines, represent about 10% of newly diagnosed malignant tumors in the United States. Among these, Multiple Myeloma survival has improved over the last decade, with the emergence of cutting-edge therapies like CAR… Read More
To arrange a conversation with our proficient medical and scientific affairs experts and discover how we can help your clinical trials with tailored imaging solutions
The evolution of cancer treatment is experiencing the emergence of immune checkpoint blockade as a promising strategy with distinct response patterns and challenges. Medical imaging plays a pivotal role in evaluating responses to immunotherapy and monitoring immune-related adverse events, challenging… Read More
Overview: Imaging Endpoints (IE) has established a strong reputation for quality through a perfect inspection record and remarkable marketing authorization success rate and is expanding its quality leadership by integrating the new standards of ICH E6 (R3) into IE’s Quality… Read More
May 7, 2024 SCOTTSDALE, AZ – Imaging Endpoints (IE), a global leader in Imaging CRO technologies and services, has announced the formation of a new subsidiary, Revolution EndpointsTM, focused on leveraging the Company’s strong leadership and financial position to acquire… Read More
On Tuesday, 23 April 2024, the U.S. FDA granted accelerated approval to Day One Biopharmaceuticals for tovorafenib, the first targeted therapy for relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG). As explained in Day One’s press release, “pLGG is the… Read More
Featured Webinar:
Radiologic Analysis of COVID-19 Infection
June 23, 2020
